Therapeutic for Acute Lung Injury

OCR Number: OCR 7222

Description:

Low-dose of ChemoRx Prevents/Treats Acute Lung Injury

- About the indications/in vivo models
  - ALI/ARDS LPS Injury Model
  - Acid-induced Lung Injury
  - Clinical utility: Emergency Department, ICU’s

- About the target/specificity
  - Well-characterized enzyme & pathway
  - Target validated by KO
  - OCR7222 acts on ALI in a target-specific mechanism

- Mechanism
  - Biology well-characterized
  - Surprising result: cell-specific biological response is favorable, unlike tissue-wide induction of pathway.

- About the agent
  - Oral small molecule
  - Approved for oncology indications via oral delivery
  - OCR7222 composition is generic or comes off patent 2021-23

- Novelty
  - New indication
  - Ultra-low effective dose 1/40 of chemotherapeutic dose
  - Novel route of delivery: inhalation

- OCR7222 IP Status:
  - Unpublished
  - Provisional patent filed
  - Both available under CDA

PI: Dianqing Wu

Licensing Contact: David Lewin
david.lewin@yale.edu